Combined modality treatment yielded a 5-year overall survival rate of 36.4% compared to 0% for non-combined treatment in patients with extraskeletal Ewing's sarcoma.
Observational (n=18)
No
What are the clinical features, treatment outcomes, and prognostic factors for patients with Extraskeletal Ewing's sarcoma?
Extraskeletal Ewing's sarcoma is common in adolescents and often presents as a localized mass; combined modality therapy is recommended, with metastasis at diagnosis and treatment mode serving as key prognostic factors.
Absolute Event Rate: 36.4% vs 0%
p-value: p=0.05
BACKGROUND AND OBJECTIVE: Extraskeletal Ewing's sarcoma (EES) is a rare, rapidly growing, round-cell, malignant tumor that can develop in the soft tissues at any location. This study was to analyze the clinical features, diagnosis and treatment of EES. METHODS: Clinical data of 18 patients with EES, treated at between Cancer Center of Sun Yat-sen University between 1995 and 2007, were analyzed. RESULTS: Of the 18 patients, 13 were male and 8 were female, aged from 8 months to 60 years. Twelve (66.7%) patients were between 5-25 years of age. Eight (44.4%) patients had tumors originated from low extremities.Sixteen patients had masses at their first visit. Sixteen patients were treated by the combined modality therapy, and 2 patients were treated by the single modality therapy. The 1-, 3- and 5- year actuarial survival rates were 82.4%, 64.2% and 32.1%, respectively. The presence of metastatic disease at the time of diagnosis and the mode of treatment were prognostic factors. CONCLUSIONS: EES is common in adolescent. It often manifests as a localized mass. The combined modality therapy is recommended for this disease. The presence of metastatic disease at the time of diagnosis and the mode of treatment are prognostic factors.
Xie et al. (Mon,) conducted a observational in Extraskeletal Ewing's sarcoma (n=18). Combined modality treatment vs. Non-combined modality treatment was evaluated on 5-year overall survival rate (p=0.05). Combined modality treatment yielded a 5-year overall survival rate of 36.4% compared to 0% for non-combined treatment in patients with extraskeletal Ewing's sarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: